CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

Area of Science:

• Hematology
• Immunology
• Pediatric Oncology

Background:

• Acute myeloid leukemia (AML) treatment in children requires novel strategies due to differences from adult AML.
• Current immunotherapies for AML face challenges with heterogeneity and specific targeting.
• Identifying pediatric-specific immunotargets is crucial for advancing treatment.

Purpose of the Study:

• To analyze immunotarget expression in pediatric acute myeloid leukemia (AML).
• To compare pediatric AML immunotarget profiles with those in adult AML.
• To identify potential targets for combinatorial immunotherapy in pediatric AML.

Main Methods:

• Whole RNA sequencing of bone marrow samples from pediatric AML patients and healthy donors.
• Flow cytometry to assess surface expression of putative target antigens.
• Principal component analysis to cluster pediatric AML samples.

Main Results:

• Pediatric AML samples clustered separately from healthy myeloid precursors.
• CD33 and CLEC12A were highly upregulated on both RNA and surface levels in pediatric AML.
• KMT2A-mutated infant AML showed FLT3 overexpression, suggesting CD33/FLT3 cotargeting.
• CLEC12A and CD33 were not expressed on hematopoietic stem cells, unlike CD33 and FLT3.

Conclusions:

• Immunotarget expression in pediatric AML differs significantly from adult AML.
• CLEC12A and CD33 are identified as promising combinatorial immunotargets for pediatric AML.
• CD33 and FLT3 represent specific targets for KMT2A-mutated infant AML.